Genetic testing company 23andMe is making major changes, including cutting 40% of its workforce and stopping development of its health treatments.
The company says these moves are necessary to focus on its core business of consumer genetic testing and research partnerships.
23andMe's value has fallen due to a massive data breach in 2023, leaving it with limited options.
The company is exploring potential licensing agreements and asset sales for its health treatments as part of its restructuring plan.
